NovoEight reports success in GUARDIAN-2 trial for Haemophilia A - Novo Nordisk
Novo Nordisk announced new phase III interim data from its GUARDIAN-2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with Haemophilia A when used as a preventative treatment. The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the GUARDIAN clinical programme that found NovoEight demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.